Optimization of conditions for secretion of dengue virus type 2 envelope domain III using Pichia pastoris

Journal of Bioscience and Bioengineering

Volumn 110, Issue 4, 2010, Pages 408-414

  Batra, Gaurav ^a   Gurramkonda, Chandrasekhar ^a   Nemani, Satish Kumar ^a   Jain, Swatantra Kumar ^b   Swaminathan, Sathyamangalam ^a   Khanna, Navin ^a  

^a INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

^b HAMDARD UNIVERSITY   (India)

Author keywords

Dengue; Envelope domain III; Fed batch cultivation; Flavivirus; Pichia pastoris; Vaccine

Indexed keywords

DENGUE; ENVELOPE DOMAINS; FED-BATCH CULTIVATION; FLAVIVIRUS; PICHIA PASTORIS;

CLONING; METHANOL; OPTIMIZATION; VACCINES; VIRUSES;

CHEMICAL ANALYSIS;

METHANOL; SEDIII 2 PROTEIN; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ARTICLE; BIOREACTOR; CULTURE MEDIUM; DENGUE VIRUS 2; FED BATCH CULTURE; NONHUMAN; PH; PICHIA PASTORIS; PROTEIN SECRETION; TEMPERATURE;

BIOMASS; BIOREACTORS; CHROMATOGRAPHY, LIQUID; CULTURE MEDIA; DENGUE VIRUS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HYDROGEN-ION CONCENTRATION; PICHIA; RECOMBINATION, GENETIC; TEMPERATURE; VIRAL PROTEINS;

DENGUE VIRUS TYPE 2; FLAVIVIRUS; PICHIA PASTORIS;

EID: 77956651000     PISSN: 13891723     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbiosc.2010.05.001     Document Type: Article

References (43)

1. Swaminathan S., Khanna N. Dengue: recent advances in biology and current status of translational research. Curr. Mol. Med. 2009, 9:152-173.
2. Gubler D.J., Kuno G., Markoff L. Flaviviruses. Field's Virology 2007, 1153-1252. Lippincott Williams & Wilkins, Philadelphia. D.M. Knipe, P.M. Howley (Eds.).
3. Whitehead S.S., Blaney J.E., Durbin A.P., Murphy B.R. Prospects for a dengue virus vaccine. Nat. Rev. Microbiol. 2007, 5:518-528.
4. Simmons M., Murphy G.S., Hayes C.G. Short report: antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine. Am. J. Trop. Med. Hyg. 2001, 65:159-161.
5. Mota J., Acosta M., Argotte R., Figueroa R., Mendez A., Ramos C. Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein. Vaccine 2005, 23:3469-3476.
6. Brandler S., Lucas-Hourani M., Moris A., Frenkiel M.P., Combredet C., Fevrier M., Bedouelle H., Schwartz O., Despres P., Tangy F. Pediatric measles vaccine expressing a dengue antigen induces durable serotype-specific neutralizing antibodies to dengue virus. PLoS. Negl. Trop. Dis. 2007, 1:e96.
7. Leng C.H., Liu S.J., Tsai J.P., Li Y.S., Chen M.Y., Liu H.H., Lien S.P., Yueh A., Hsiao K.N., Lai L.W., Liu F.C., Chong P., Chen H.W. A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity. Microbes Infect. 2009, 11:288-295.
8. Khanam S., Khanna N., Swaminathan S. Induction of neutralizing antibodies and T cell responses by dengue virus type 2 envelope domain III encoded by plasmid and adenoviral vectors. Vaccine 2006, 24:6513-6525.
9. Khanam S., Etemad B., Khanna N., Swaminathan S. Induction of neutralizing antibodies specific to dengue virus serotypes 2 and 4 by a bivalent antigen composed of linked envelope domains III of these two serotypes. Am. J. Trop. Med. Hyg. 2006, 74:266-277.
10. Khanam S., Rajendra P., Khanna N., Swaminathan S. An adenovirus prime/plasmid boost strategy for induction of equipotent immune responses to two dengue virus serotypes. BMC Biotechnol. 2007, 7:10.
11. Etemad B., Batra G., Raut R., Dahiya S., Khanam S., Swaminathan S., Khanna N. An envelope domain III-based chimeric antigen produced in Pichia pastoris elicits neutralizing antibodies against all four dengue virus serotypes. Am. J. Trop. Med. Hyg. 2008, 79:353-363.
12. Modis Y., Ogata S., Clements D., Harrison S.C. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:6986-6991.
13. Kuhn R.J., Zhang W., Rossmann M.G., Pletnev S.V., Corver J., Lenches E., Jones C.T., Mukhopadhyay S., Chipman P.R., Strauss E.G., Baker T.S., Strauss J.H. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 2002, 108:717-725.
14. Chen Y., Maguire T., Hileman R.E., Fromm J.R., Esko J.D., Linhardt R.J., Marks R.M. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat. Med. 1997, 3:866-871.
15. Crill W.D., Roehrig J.T. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J. Virol. 2001, 75:7769-7773.
16. Hung J.J., Hsieh M.T., Young M.J., Kao C.L., King C.C., Chang W. An external loop region of domain III of dengue virus type 2 envelope protein is involved in serotype-specific binding to mosquito but not mammalian cells. J. Virol. 2004, 78:378-388.
17. Sukupolvi-Petty S., Austin S.K., Purtha W.E., Oliphant T., Nybakken G.E., Schlesinger J.J., Roehrig J.T., Gromowski G.D., Barrett A.D., Fremont D.H., Diamond M.S. Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J. Virol. 2007, 81:12816-12826.
18. Gromowski G.D., Barrett A.D. Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. Virology 2007, 366:349-360.
19. Gromowski G.D., Barrett N.D., Barrett A.D. Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus. J. Virol. 2008, 82:8828-8837.
20. Jaiswal S., Khanna N., Swaminathan S. High-level expression and one-step purification of recombinant dengue virus type 2 envelope domain III protein in Escherichia coli. Protein Expr. Purif. 2004, 33:80-91.
21. Chin J.F., Chu J.J., Ng M.L. The envelope glycoprotein domain III of dengue virus serotypes 1 and 2 inhibit virus entry. Microbes Infect. 2007, 9:1-6.
22. Bhardwaj S., Holbrook M., Shope R.E., Barrett A.D., Watowich S.J. Biophysical characterization and vector-specific antagonist activity of domain III of the tick-borne flavivirus envelope protein. J. Virol. 2001, 75:4002-4007.
23. Yu S., Wuu A., Basu R., Holbrook M.R., Barrett A.D., Lee J.C. Solution structure and structural dynamics of envelope protein domain III of mosquito- and tick-borne flaviviruses. Biochemistry 2004, 43:9168-9176.
24. Beasley D.W., Holbrook M.R., Travassos Da Rosa A.P., Coffey L., Carrara A.S., Phillippi-Falkenstein K., Bohm Jr.R.P., Ratterree Jr.M.S., Lillibridge K.M., Ludwig G.V., Estrada-Franco J., Weaver SC., Tesh RB., Shope RE., other 5 authors Use of a recombinant envelope protein subunit antigen for specific serological diagnosis of West Nile virus infection. J. Clin. Microbiol. 2004, 42:2759-2765.
25. Liao M., Kielian M. Domain III from class II fusion proteins functions as a dominant-negative inhibitor of virus membrane fusion. J. Cell Biol. 2005, 171:111-120.
26. Saejung W., Puttikhunt C., Prommool T., Sojikul P., Tanaka R., Fujiyama K., Malasit P., Seki T. Enhancement of recombinant soluble dengue virus 2 envelope domain III protein production in Escherichia coli trxB and gor double mutant. J. Biosci. Bioeng. 2006, 102:333-339.
27. Matsui K., Gromowski G.D., Li L., Schuh A.J., Lee J.C., Barrett A.D. Characterization of dengue complex-reactive epitopes on dengue 3 virus envelope protein domain III. Virology 2009, 384:16-20.
28. Simmons M., Porter K.R., Escamilla J., Graham R., Watts D.M., Eckels K.H., Hayes C.G. Evaluation of recombinant dengue viral envelope B domain protein antigens for the detection of dengue complex-specific antibodies. Am. J. Trop. Med. Hyg. 1998, 58:144-151.
29. Saejung W., Fujiyama K., Takasaki T., Ito M., Hori K., Malasit P., Watanabe Y., Kurane I., Seki T. Production of dengue 2 envelope domain III in plant using TMV-based vector system. Vaccine 2007, 25:6646-6654.
30. Gurramkonda C., Adnan A., Gabel T., Lunsdorf H., Ross A., Nemani S.K., Swaminathan S., Khanna N., Rinas U. Simple high-cell density fed-batch technique for high-level recombinant protein production with Pichia pastoris: application to intracellular production of Hepatitis B surface antigen. Microb. Cell Fact. 2009, 8:13.
31. Boettner M., Prinz B., Holz C., Stahl U., Lang C. High-throughput screening for expression of heterologous proteins in the yeast Pichia pastoris. J. Biotechnol. 2002, 99:51-62.
32. Liu R.S., Yang K.Y., Lin J., Lin Y.W., Zhang Z.H., Zhang J., Xia N.S. High-yield expression of recombinant SARS coronavirus nucleocapsid protein in methylotrophic yeast Pichia pastoris. World J. Gastroenterol. 2004, 10:3602-3607.
33. Smith P.K., Krohn R.I., Hermanson G.T., Mallia A.K., Gartner F.H., Provenzano M.D., Fujimoto E.K., Goeke N.M., Olson B.J., Klenk D.C. Measurement of protein using bicinchoninic acid. Anal. Biochem. 1985, 150:76-85.
34. Shi X., Karkut T., Chamankhah M., Alting-Mees M., Hemmingsen S.M., Hegedus D. Optimal conditions for the expression of a single-chain antibody (scFv) gene in Pichia pastoris. Protein Expr. Purif. 2003, 28:321-330.
35. Nakamura T., Zamocky M., Zdrahal Z., Chaloupkova R., Monincova M., Prokop Z., Nagata Y., Damborsky J. Expression of glycosylated haloalkane dehalogenase LinB in Pichia pastoris. Protein Expr. Purif. 2006, 46:85-91.
36. Dragosits M., Stadlmann J., Albiol J., Baumann K., Maurer M., Gasser B., Sauer M., Altmann F., Ferrer P., Mattanovich D. The effect of temperature on the proteome of recombinant Pichia pastoris. J. Proteome Res. 2009, 8:1380-1392.
37. Jahic M., Wallberg F., Bollok M., Garcia P., Enfors S.O. Temperature limited fed-batch technique for control of proteolysis in Pichia pastoris bioreactor cultures. Microb. Cell Fact. 2003, 2:6.
38. Wang J., Nguyen V., Glen J., Henderson B., Saul A., Miller L.H. Improved yield of recombinant merozoite surface protein 3 (MSP3) from Pichia pastoris using chemically defined media. Biotechnol. Bioeng. 2005, 90:838-847.
39. Toonkool P., Metheenukul P., Sujiwattanarat P., Paiboon P., Tongtubtim N., Ketudat-Cairns M., Ketudat-Cairns J., Svasti J. Expression and purification of dalcochinase, a β-glucosidase from Dalbergia cochinchinensis Pierre, in yeast and bacterial hosts. Protein Expr. Purif. 2006, 48:195-204.
40. Rosenfeld S.A. Use of Pichia pastoris for expression of recombinant proteins. Methods Enzymol. 1999, 306:154-169.
41. Cos O., Ramon R., Montesinos J.L., Valero F. Operational strategies, monitoring and control of heterologous protein production in the methylotrophic yeast Pichia pastoris under different promoters: A review. Microb. Cell Fact. 2006, 5:17.
42. Charoenrat T., Ketudat-Cairns M., Stendahl-Andersen H., Jahic M., Enfors S.O. Oxygen-limited fed-batch process: an alternative control for Pichia pastoris recombinant protein processes. Bioproc. Biosyst. Eng. 2005, 27:399-406.
43. Khatri N.K., Hoffmann F. Oxygen-limited control of methanol uptake for improved production of a single-chain antibody fragment with recombinant Pichia pastoris. Appl. Microbiol. Biotechnol. 2006, 72:492-498.